Results 91 to 100 of about 4,828 (174)

Informe técnico palivizumab inyectable

, 2016
En base a la revisión de la información científica respecto al medicamento Palivizumab 50mg inyectable, el Equipo Técnico acuerda no incluirlo en la Lista Complementaria de medicamentos al Petitorio Nacional Único de Medicamentos Esenciales (PNUME) debido a que no reduce la mortalidad y no es costo efectivo.
openaire   +1 more source

Genomic Surveillance and Antigenic Characterization of Respiratory Syncytial Virus (RSV) in Spain During the 2023-2024 Season of Nirsevimab Administration. [PDF]

J Infect Dis
Iglesias-Caballero M, Mas V, Campoy A, Calvo C, García ML, Alcolea S, Moreno-Parrado L, Reina J, Navascués A, Antón A, Davina-Nunez C, Perez-Castro S, Costa J, Fernández-González A, Lepe JA, Gaona C, Pérez Z, García-Martínez de Artola D, Vázquez-Morón S, Camarero S, Cano O, Pozo F, Casas I.   +22 more
europepmc   +1 more source

Recommendation for use of a long-acting monoclonal antibody to prevent respiratory syncytial virus infection in infants and young children. [PDF]

Clin Exp Pediatr
Choi SH, Kim DH, Ahn JG, Yun KW, Eun BW, Lee J, Lee J, Lee TJ, Lee H, Jo DS, Cho EY, Cho HK, Choe YJ, Choi UY, Kim YK, Committee on Infectious Diseases of the Korean Pediatric Society.   +15 more
europepmc   +1 more source

Complementary Strategy of Maternal Immunization with RSVpreF Vaccine and Monoclonal Antibodies for the Prevention of Respiratory Syncytial Virus Among Italian Infants: A Cost-Effectiveness Assessment. [PDF]

Infect Dis Ther
Polistena B, Midulla F, Sotgiu G, d'Angela D, Di Virgilio R, Spandonaro F.   +5 more
europepmc   +1 more source

iBody-mediated tuning of synthetic cytokine receptor activation via rational nanobody interface engineering. [PDF]

MAbs
Kunze R, Navratil F, Beichert J, Geyer F, Floss DM, Kolmar H, Scheller J, Pudewell S.   +7 more
europepmc   +1 more source

Clesrovimab approval for RSV: a lifesaving opportunity for global infant health equity. [PDF]

Ann Med Surg (Lond)
Kumari S, Kamil KA.
europepmc   +1 more source

Estimating the Public Health and Economic Impact of Immunisation with Nirsevimab or Maternal Immunisation for the Prevention of RSV-Related Outcomes Over Infants' First RSV Season in the UK. [PDF]

Infect Dis Ther
Chetty M, Costello P, Yarnoff B, Musci R, Ghemmouri M.   +4 more
europepmc   +1 more source

Palivizumab.

Indian pediatrics, 2002
D, Gupta, P, Gupta
openaire   +1 more source

Virus-like Particle Vaccines Containing RSV Fusion Protein Cleavage Mutations Are Immunogenic and Protective in Cotton Rats With a Prime Dose. [PDF]

Immune Netw
Hwang HS, Kwon YM, Kim KH, Lee YT, Ko EJ, Meas A, Kang SM.   +6 more
europepmc   +1 more source

RSV Prevention in Infants and Young Children. [PDF]

Am J Respir Crit Care Med
Cacho F, Sockrider M.
europepmc   +1 more source